375 related articles for article (PubMed ID: 33189148)
21. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Anastasilakis AD; Polyzos SA; Makras P
Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension.
Ramchand SK; David NL; Lee H; Eastell R; Tsai JN; Leder BZ
J Bone Miner Res; 2021 May; 36(5):921-930. PubMed ID: 33507574
[TBL] [Abstract][Full Text] [Related]
23. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
[TBL] [Abstract][Full Text] [Related]
24. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
Hong N; Shin S; Lee S; Kim KJ; Rhee Y
Calcif Tissue Int; 2022 Jul; 111(1):47-55. PubMed ID: 35226133
[TBL] [Abstract][Full Text] [Related]
25. [Different Perspectives of Drug Holiday and Combination Therapies When Treating Osteoporosis].
Oser S; Häuselmann HJ
Praxis (Bern 1994); 2021; 110(16):975-983. PubMed ID: 34875857
[TBL] [Abstract][Full Text] [Related]
26. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
Cosman F
Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
[TBL] [Abstract][Full Text] [Related]
27. Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study.
Yang D; Tan J; Long Y; Huang K; Han W; Wang M; Zhu S; Zeng S; Yi W
Aging Clin Exp Res; 2023 Mar; 35(3):531-539. PubMed ID: 36708462
[TBL] [Abstract][Full Text] [Related]
28. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
29. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
[TBL] [Abstract][Full Text] [Related]
30. Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.
Asano T; Shimizu T; Takahashi D; Ota M; Sato D; Hamano H; Hiratsuka S; Takahata M; Iwasaki N
J Bone Miner Metab; 2019 Mar; 37(2):351-357. PubMed ID: 29721807
[TBL] [Abstract][Full Text] [Related]
31. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.
Cosman F; McMahon D; Dempster D; Nieves JW
J Bone Miner Res; 2020 Feb; 35(2):219-225. PubMed ID: 31419313
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
[No Abstract] [Full Text] [Related]
33. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Tsai JN; Uihlein AV; Lee H; Kumbhani R; Siwila-Sackman E; McKay EA; Burnett-Bowie SA; Neer RM; Leder BZ
Lancet; 2013 Jul; 382(9886):50-6. PubMed ID: 23683600
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis.
Ebina K; Kashii M; Hirao M; Hashimoto J; Noguchi T; Koizumi K; Kitaguchi K; Matsuoka H; Iwahashi T; Tsukamoto Y; Yoshikawa H
J Bone Miner Metab; 2017 Sep; 35(5):571-580. PubMed ID: 27830384
[TBL] [Abstract][Full Text] [Related]
35. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
36. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
37. Four-Year Teriparatide Followed by Denosumab
Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
[TBL] [Abstract][Full Text] [Related]
38. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
Cosman F; Nieves JW; Dempster DW
J Bone Miner Res; 2017 Feb; 32(2):198-202. PubMed ID: 27925287
[TBL] [Abstract][Full Text] [Related]
39. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
[TBL] [Abstract][Full Text] [Related]
40. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
Ebina K; Hirao M; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Okamura G; Etani Y; Takami K; Goshima A; Nakata K
Bone; 2020 Nov; 140():115574. PubMed ID: 32777516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
